[144] Edwards Lifesciences Corp SEC Filing
Edwards Lifesciences (EW) Form 144 notifies of a proposed sale of 2,500 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of $204,865.00. The sale is scheduled to occur approximately on 08/25/2025 on the NYSE. The shares being offered were acquired as equity compensation: 657 shares from RSU/PSU on 05/08/2022, 1,671 shares from a restricted stock lapse on 05/17/2022, and 172 shares from a restricted stock lapse on 05/03/2023. No securities were reported sold in the past three months on this form. The filer certifies compliance with the Rule 144 representation regarding material nonpublic information.
Edwards Lifesciences (EW) - Il modulo 144 segnala la proposta di vendita di 2.500 azioni ordinarie tramite Charles Schwab & Co., Inc., per un valore di mercato complessivo di $204.865,00. La vendita 猫 prevista approssimativamente il 25/08/2025 sul NYSE. Le azioni offerte derivano da compensi in azioni: 657 azioni da RSU/PSU acquisite il 08/05/2022, 1.671 azioni da vesting di azioni vincolate il 17/05/2022 e 172 azioni da vesting il 03/05/2023. Nel modulo non risultano vendite di titoli nei tre mesi precedenti. Il dichiarante certifica il rispetto della rappresentazione prevista dalla Rule 144 riguardo a informazioni aziendali materiali non pubbliche.
Edwards Lifesciences (EW) - El Formulario 144 notifica una propuesta de venta de 2.500 acciones ordinarias a trav茅s de Charles Schwab & Co., Inc., por un valor de mercado agregado de $204.865,00. La venta est谩 programada aproximadamente para el 25/08/2025 en la NYSE. Las acciones ofrecidas provienen de compensaci贸n accionaria: 657 acciones de RSU/PSU el 08/05/2022, 1.671 acciones por liberaci贸n de acciones restringidas el 17/05/2022 y 172 acciones por liberaci贸n el 03/05/2023. En este formulario no se reportaron ventas de valores en los 煤ltimos tres meses. El declarante certifica el cumplimiento de la declaraci贸n exigida por la Rule 144 respecto a informaci贸n material no p煤blica.
Edwards Lifesciences (EW) - Form 144電� Charles Schwab & Co., Inc.毳� 韱淀暣 2,500欤检潣 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橂┌, 齑� 鞁滉皜齑濎暋鞚� $204,865.00鞛呺媹雼�. 毵り皝 鞓堨爼鞚检潃 雽�霝� 2025-08-25搿�, NYSE鞐愳劀 歆勴枆霅� 鞓堨爼鞛呺媹雼�. 鞝滌嫓霅� 欤检嫕鞚� 欤检嫕 氤挫儊鞙茧 旆摑霅� 瓴冹溂搿�, 2022-05-08鞐� RSU/PSU搿� 旆摑頃� 657欤�, 2022-05-17鞐� 鞝滍暅欤� 甓岆Μ頇曤寑搿� 鞚疙暅 1,671欤�, 2023-05-03鞐� 鞝滍暅欤� 甓岆Μ頇曤寑搿� 鞚疙暅 172欤检瀰雼堧嫟. 鞚� 靹滊鞐愲姅 歆�雮� 3臧滌洈 雮� 毵る弰 氤搓碃臧� 鞐嗢姷雼堧嫟. 鞁犼碃鞚胳潃 欷戩殧 牍勱车臧� 鞝曤炒鞕� 甏�霠暅 Rule 144 歆勳垹 欷�靾橂ゼ 鞚胳頃╇媹雼�.
Edwards Lifesciences (EW) - Le formulaire 144 notifie une proposition de vente de 2 500 actions ordinaires via Charles Schwab & Co., Inc., pour une valeur de march茅 totale de $204 865,00. La vente est pr茅vue approximativement le 25/08/2025 sur le NYSE. Les actions propos茅es proviennent d'une r茅mun茅ration en actions : 657 actions issues de RSU/PSU le 08/05/2022, 1 671 actions r茅sultant de la lev茅e de restrictions le 17/05/2022 et 172 actions le 03/05/2023. Aucune vente de titres n'est d茅clar茅e sur ce formulaire au cours des trois derniers mois. Le d茅clarant certifie le respect de la repr茅sentation exig茅e par la Rule 144 concernant les informations mat茅rielles non publiques.
Edwards Lifesciences (EW) - Formular 144 meldet einen geplanten Verkauf von 2.500 Stammaktien 眉ber Charles Schwab & Co., Inc. mit einem gesamten Marktwert von $204.865,00. Der Verkauf soll voraussichtlich am 25.08.2025 an der NYSE stattfinden. Die angebotenen Aktien stammen aus aktienbasierter Verg眉tung: 657 Aktien aus RSU/PSU am 08.05.2022, 1.671 Aktien durch Vesting eingeschr盲nkter Aktien am 17.05.2022 und 172 Aktien durch Vesting am 03.05.2023. In den letzten drei Monaten wurden in diesem Formular keine Verk盲ufe gemeldet. Der Melder best盲tigt die Einhaltung der Rule-144-Erkl盲rung bez眉glich wesentlicher nicht枚ffentlicher Informationen.
- Clear compliance with Rule 144 disclosure requirements including broker, exchange, share count, and acquisition details
- Securities originated from equity compensation (RSU/PSU and restricted stock lapse), not from recent open-market purchases
- Proposed sale of 2,500 shares valued at $204,865 could be viewed negatively by some investors if perceived as insider selling
- Filer identity and post-sale holdings are not disclosed on this form, limiting assessment of insider's remaining exposure
Insights
TL;DR Insider intends to sell 2,500 EW shares (approx. $205k) acquired via equity compensation; disclosure appears routine under Rule 144.
The filing shows a proposed disposition executed through Charles Schwab with the sale date set for 08/25/2025. The lots originated from equity compensation events in 2022 and 2023, indicating these are previously granted shares rather than newly purchased open-market buys. The absence of reported sales in the prior three months suggests this notice is not part of an ongoing rapid divestiture pattern. From a disclosure and compliance standpoint, the form fulfils Rule 144 notice requirements by identifying broker, share counts, acquisition dates, and nature of acquisition.
TL;DR The filing is a standard insider sale notice; documentation and representations required by Rule 144 are present.
The details provided鈥攂roker name, exchange, share counts, acquisition method, and certification about material nonpublic information鈥攁re consistent with standard governance practices for pre-regulation insider sales. The holdings were acquired through RSU/PSU grants and restricted stock lapses, which is common for employees/executives. The filing does not disclose the seller's title or aggregate post-sale holdings, limiting assessment of potential governance implications.
Edwards Lifesciences (EW) - Il modulo 144 segnala la proposta di vendita di 2.500 azioni ordinarie tramite Charles Schwab & Co., Inc., per un valore di mercato complessivo di $204.865,00. La vendita 猫 prevista approssimativamente il 25/08/2025 sul NYSE. Le azioni offerte derivano da compensi in azioni: 657 azioni da RSU/PSU acquisite il 08/05/2022, 1.671 azioni da vesting di azioni vincolate il 17/05/2022 e 172 azioni da vesting il 03/05/2023. Nel modulo non risultano vendite di titoli nei tre mesi precedenti. Il dichiarante certifica il rispetto della rappresentazione prevista dalla Rule 144 riguardo a informazioni aziendali materiali non pubbliche.
Edwards Lifesciences (EW) - El Formulario 144 notifica una propuesta de venta de 2.500 acciones ordinarias a trav茅s de Charles Schwab & Co., Inc., por un valor de mercado agregado de $204.865,00. La venta est谩 programada aproximadamente para el 25/08/2025 en la NYSE. Las acciones ofrecidas provienen de compensaci贸n accionaria: 657 acciones de RSU/PSU el 08/05/2022, 1.671 acciones por liberaci贸n de acciones restringidas el 17/05/2022 y 172 acciones por liberaci贸n el 03/05/2023. En este formulario no se reportaron ventas de valores en los 煤ltimos tres meses. El declarante certifica el cumplimiento de la declaraci贸n exigida por la Rule 144 respecto a informaci贸n material no p煤blica.
Edwards Lifesciences (EW) - Form 144電� Charles Schwab & Co., Inc.毳� 韱淀暣 2,500欤检潣 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橂┌, 齑� 鞁滉皜齑濎暋鞚� $204,865.00鞛呺媹雼�. 毵り皝 鞓堨爼鞚检潃 雽�霝� 2025-08-25搿�, NYSE鞐愳劀 歆勴枆霅� 鞓堨爼鞛呺媹雼�. 鞝滌嫓霅� 欤检嫕鞚� 欤检嫕 氤挫儊鞙茧 旆摑霅� 瓴冹溂搿�, 2022-05-08鞐� RSU/PSU搿� 旆摑頃� 657欤�, 2022-05-17鞐� 鞝滍暅欤� 甓岆Μ頇曤寑搿� 鞚疙暅 1,671欤�, 2023-05-03鞐� 鞝滍暅欤� 甓岆Μ頇曤寑搿� 鞚疙暅 172欤检瀰雼堧嫟. 鞚� 靹滊鞐愲姅 歆�雮� 3臧滌洈 雮� 毵る弰 氤搓碃臧� 鞐嗢姷雼堧嫟. 鞁犼碃鞚胳潃 欷戩殧 牍勱车臧� 鞝曤炒鞕� 甏�霠暅 Rule 144 歆勳垹 欷�靾橂ゼ 鞚胳頃╇媹雼�.
Edwards Lifesciences (EW) - Le formulaire 144 notifie une proposition de vente de 2 500 actions ordinaires via Charles Schwab & Co., Inc., pour une valeur de march茅 totale de $204 865,00. La vente est pr茅vue approximativement le 25/08/2025 sur le NYSE. Les actions propos茅es proviennent d'une r茅mun茅ration en actions : 657 actions issues de RSU/PSU le 08/05/2022, 1 671 actions r茅sultant de la lev茅e de restrictions le 17/05/2022 et 172 actions le 03/05/2023. Aucune vente de titres n'est d茅clar茅e sur ce formulaire au cours des trois derniers mois. Le d茅clarant certifie le respect de la repr茅sentation exig茅e par la Rule 144 concernant les informations mat茅rielles non publiques.
Edwards Lifesciences (EW) - Formular 144 meldet einen geplanten Verkauf von 2.500 Stammaktien 眉ber Charles Schwab & Co., Inc. mit einem gesamten Marktwert von $204.865,00. Der Verkauf soll voraussichtlich am 25.08.2025 an der NYSE stattfinden. Die angebotenen Aktien stammen aus aktienbasierter Verg眉tung: 657 Aktien aus RSU/PSU am 08.05.2022, 1.671 Aktien durch Vesting eingeschr盲nkter Aktien am 17.05.2022 und 172 Aktien durch Vesting am 03.05.2023. In den letzten drei Monaten wurden in diesem Formular keine Verk盲ufe gemeldet. Der Melder best盲tigt die Einhaltung der Rule-144-Erkl盲rung bez眉glich wesentlicher nicht枚ffentlicher Informationen.
FAQ
What does the Form 144 filed for Edwards Lifesciences (EW) report?
How were the shares being sold acquired?
Does the filing show recent sales of EW shares by this person?
Through which broker and exchange will the sale occur?
Does the filer assert they possess any material nonpublic information?
